Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 9/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5376901 | 0.89 | METAP2 (0.66) | METAP2LMNAMAPTTP53 | |
| SCHEMBL5372134 | 0.84 | METAP2 (0.53) | METAP2MAPTKMT2AALDH1A1 | |
| SCHEMBL5391990 | 0.84 | METAP2 (0.53) | METAP2LMNAMAPTHSD17B10ALDH1A1 | |
| SCHEMBL5387535 | 0.84 | METAP2 (0.69) | METAP2MAPTALDH1A1 | |
| SCHEMBL5371852 | 0.84 | METAP2 (0.55) | METAP2GAALMNAMAPTKMT2A | |
| SCHEMBL5382902 | 0.81 | LMNA (0.48) | METAP2GAALMNAMAPTALDH1A1 | |
| SCHEMBL5393592 | 0.81 | METAP2 (0.52) | METAP2GAALMNAMAPTKMT2A | |
| SCHEMBL5371807 | 0.80 | RAB9A (0.45) | METAP2GAAKMT2ATSHRHSD17B10 | |
| SCHEMBL5385578 | 0.79 | METAP2 (0.65) | METAP2GAALMNAMAPTKMT2A | |
| SCHEMBL5376459 | 0.79 | METAP2 (0.53) | METAP2LMNAMAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1223932-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2003-01-15 | — | — | EP | claimed |
| EP-1223932-A1 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2002-07-24 | — | — | EP | claimed |
| WO-2001024796-A1 | 1,2,4-TRIAZOLE DERIVATIVES, COMPOSITION, PROCESS OF MAKING AND METHODS OF USE | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-12 | — | — | WO | claimed |
| US-7304082-B2 | 1,2,4-triazole derivatives, compositions, process of making and methods of use | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20050267185-A1 | 1,2,4-triazole derivatives, compositions, process of making and methods of use | SMITHKLINE BEECHAM CORPORATION | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267185-A1 | 1,2,4-triazole derivatives, compositions, process of making and methods of use | METAP2, METAP1, DNPEP | METAP2 1/4885GAA 2089/4885LMNA 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.